Inflammatory cytokines

Product Inquiry

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
OlitigaltinGB-0139; TD-139Phase 2 ClinicalThe University Of Edinburgh, Lund University FoundationIdiopathic Pulmonary Fibrosis; Coronavirus Disease 2019 (COVID-19)
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
OcriplasminA-01016; THR-409ApprovedThrombogenicsJetrea, JejetreaUnited StatesVitreomacular AdhesionThrombogenics Inc2012-10-17Vitreous Detachment; Arterial Occlusive Diseases; Disease Progression; Stroke; Retinal Diseases; Diabetic macular oedema; Uveitis; Vitreomacular Adhesion; Venous Thrombosis; Eye Diseases; Macular Degeneration; Diabetic Retinopathy; Retinal Vein Occlusion
Details
  • Product Inquiry
  • Marketed Drug Information
  • Clinical Drug Information
Contact Us

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8